Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era

Campbell C. et al, (2021), Frontiers in Medicine, 8

Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a

Lin S-K. et al, (2021), Virus Evolution

Divergent trajectories of antiviral memory after SARS-Cov-2 infection

Tomic* A. et al, (2021)

High cure rates for HCV genotype 6 in advanced liver fibrosis with 12 weeks sofosbuvir and daclatasvir: The Vietnam SEARCH Study

Flower B. et al, (2021), Open Forum Infectious Diseases

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy

Smith DA. et al, (2021), Journal of Viral Hepatitis

Extensive C->U transition biases in the genomes of a wide range of mammalian RNA viruses; potential associations with transcriptional mutations, damage- or host-mediated editing of viral RNA.

Simmonds P. and Ansari MA., (2021), PLoS pathogens, 17

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Frater J. et al, (2021), The Lancet HIV

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2021)

Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations

Mokaya J. et al, (2021), Journal of Viral Hepatitis

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

Cooke GS. et al, (2021), Wellcome Open Research, 6, 93 - 93

SARS-CoV-2 within-host diversity and transmission

Lythgoe KA. et al, (2021), Science, 372, eabg0821 - eabg0821

Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era

Campbell C. et al, (2021)

In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control

Ansari MA. et al, (2021), Wellcome Open Research, 6, 47 - 47

Mutation bias implicates RNA editing in a wide range of mammalian RNA viruses

Simmonds P. and Ansari MA., (2021)

Global spread and evolutionary history of HCV subtype 3a

lin S-K. et al, (2021)

Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

Cooke GS. et al, (2021)

Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection

Downs LO. et al, (2021), Wellcome Open Research, 5, 240 - 240

Epstein-Barr virus reactivation in sepsis due to community-acquired pneumonia is associated with increased morbidity and an immunosuppressed host transcriptomic endotype

Goh C. et al, (2020), Scientific Reports, 10

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Peng Y. et al, (2020), Nature Immunology, 21, 1336 - 1345

Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus

Simmonds P. et al, (2020), RNA, 26, 1541 - 1556

Load More

Include forthcoming?